How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy


Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.


By Rebecca Robbins and Sheryl Gay Stolberg | NYTimes | NYT > Business | Disclosure

Comments